GLP-1 for Weight Loss: How It Works and the Evidence

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub — evidence-based GLP-1, metabolic, and genetics education. Explore the full library any time.

GLP-1 receptor agonist medications sit at the center of the modern weight-loss conversation. Rather than ranking products, this guide focuses on what the class does, what the published evidence actually shows, how FDA labeling frames its use, where the limits are, and the genetic variables that shape every GLP-1 decision.

Compare the numbers: What GLP-1 programs actually cost per month →

How GLP-1 receptor agonists work

These medications act through agonism of the glucagon-like peptide-1 receptor; some compounds also engage the GIP receptor, and investigational compounds add glucagon receptor agonism. By engaging the GLP-1 receptor — and, for tirzepatide-based compounds, the GIP receptor — they slow gastric emptying, blunt post-meal glucose spikes, and increase satiety signaling in the hypothalamus. For many people the net effect is reduced caloric intake and improved post-prandial glycemic control, both relevant to weight management.

What the trial evidence shows

The class has been evaluated across individual product trial programs — STEP, SURPASS, SURMOUNT, SUSTAIN, PIONEER, AWARD, LEAD, and LEADER, among others. Mean weight reduction in published trials varies by compound, dose, and study population, typically reported in the literature in the range of 5–22% relative to baseline body weight at study endpoints. These outcomes reflect the manuscripts and FDA labeling, not guarantees for any individual.

FDA-approved indications and labeling

The GLP-1 class includes drugs FDA-approved for type 2 diabetes (beginning with exenatide in 2005) and for chronic weight management — liraglutide (Saxenda) in 2014, semaglutide (Wegovy) in 2021, and tirzepatide (Zepbound) in 2023. The FDA label is the controlling document on approved indications, dosing, contraindications, and warnings. Off-label prescribing exists in practice and is governed by prescriber judgment, not by marketing claims.

Limitations and who it may not suit

Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Serious adverse events reported with these medications include pancreatitis, gallbladder events, and acute kidney injury. The class carries a boxed warning for thyroid C-cell tumor risk observed in rodent studies, and it should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Review your full history with a provider first.

The genetic variable in the pathway

The Precision Peptide Genetic Test analyzes FTO, MC4R, and TCF7L2 — variants related to GLP-1 and related signaling — as part of 14 pathways, 49 peptides, 150+ genetic insights. It does not predict your response to GLP-1 medications or determine a dose; it offers pathway-level context for a conversation with your provider. Genetics here is a guide, not a guarantee. Explore the Weight Management Protocols and Semaglutide for Weight Loss.

Why response varies from person to person

The wide range reported in trials — roughly 5 to 22 percent of baseline body weight, depending on compound, dose, and population — hints at something important: results are not uniform. Two people on the same medication at the same dose can have noticeably different experiences, and that variability is one reason the idea of a single "best" GLP-1 is misleading.

The factors underneath the average

Several things shape where an individual lands. Adherence to the prescribed schedule, how the body tolerates titration, coexisting conditions, and the surrounding lifestyle context all contribute, as does baseline biology. Averages describe populations, not people, which is why a clinician frames realistic expectations rather than promising a number. Understanding this upfront also reframes what genetic context can and cannot do: it is background that may help explain tendencies in appetite and energy balance, never a forecast of how many pounds a given drug will produce. The most useful version of "best" is the option that fits your indication, your tolerance, and your goals, chosen with a provider.

Frequently Asked Questions About GLP-1 for Weight Loss

How do GLP-1 medications support weight loss?

They act through agonism of the GLP-1 receptor, and in some compounds the GIP receptor as well. By slowing gastric emptying, blunting post-meal glucose spikes, and increasing satiety signaling, they tend to reduce caloric intake for many people. Individual results vary by compound, dose, and study population per the trial data.

How much weight do trials report?

Published trials report mean weight reduction in the range of roughly 5–22% relative to baseline body weight at study endpoints, varying by compound, dose, and population. These figures come from the trial manuscripts and FDA labeling and are not guarantees for any individual, which is why a provider frames realistic expectations.

Who should avoid GLP-1 medications?

The class carries a boxed warning for thyroid C-cell tumor risk and should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Anyone considering therapy should review their full medical history with a qualified provider first.

Can a genetic test pick the best GLP-1 for me?

No. The Precision Peptide Genetic Test does not predict response or determine a dose. It analyzes variants such as FTO and MC4R, and TCF7L2 that relate to GLP-1 signaling and energy balance, offering pathway-level context that supports a more informed conversation with your provider.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.